Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19

Some systemic and biologic psoriasis treatments [SBT] have been associated with an increased risk of infection.1 To date, more and more data regarding the risk of COVID-19 infection in patients receiving SBT becomes available.2-5 To enrich these data, we evaluated the frequency of severe COVID-19 infections, defined as hospitalisation or death, in psoriasis patients receiving SBT, especially during the 4 months following SBT initiation.

[1]  G. Pellacani,et al.  Evolution of COVID‐19 infection in four psoriatic patients treated with biological drugs , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  V. Marmol,et al.  Improvement of SARS‐CoV‐2 symptoms following Guselkumab injection in a psoriatic patient , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  R. Balestri,et al.  SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐17 inhibitor , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  N. Bragazzi,et al.  Biologics increase the risk of SARS‐CoV‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration , 2020, Dermatologic therapy.

[5]  L. Naldi,et al.  The impact of the COVID‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience , 2020, The British journal of dermatology.

[6]  M. Rybojad,et al.  Vascular skin symptoms in COVID‐19: a French observational study , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  David Berlin,et al.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.

[8]  M. Lebwohl,et al.  Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). , 2015, JAMA dermatology.

[9]  F. Drago,et al.  Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects. , 2015, Autoimmunity reviews.